Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. more
Time Frame | TRML | Sector | S&P500 |
---|---|---|---|
1-Week Return | -18.5% | -3.39% | -3.47% |
1-Month Return | -18.96% | -3.25% | -0.29% |
3-Month Return | -5.38% | -11.61% | 4.5% |
6-Month Return | 27.78% | -5.89% | 6.91% |
1-Year Return | 4.58% | 2.65% | 23.79% |
3-Year Return | -86.62% | 0.56% | 28.43% |
5-Year Return | -87.77% | 34.63% | 83.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 379.00K | 447.00K | 623.00K | 6.00K | 33.00K | [{"date":"2019-12-31","value":60.83,"profit":true},{"date":"2020-12-31","value":71.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.96,"profit":true},{"date":"2023-12-31","value":5.3,"profit":true}] |
Gross Profit | (379.00K) | (447.00K) | (623.00K) | (6.00K) | (33.00K) | [{"date":"2019-12-31","value":-37900000,"profit":false},{"date":"2020-12-31","value":-44700000,"profit":false},{"date":"2021-12-31","value":-62300000,"profit":false},{"date":"2022-12-31","value":-600000,"profit":false},{"date":"2023-12-31","value":-3300000,"profit":false}] |
Gross Margin | - | - | - | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 18.00M | 22.24M | 904.00 | 19.70M | 45.41M | [{"date":"2019-12-31","value":39.64,"profit":true},{"date":"2020-12-31","value":48.97,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":43.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (18.38M) | (22.68M) | (904.00) | (19.70M) | (45.41M) | [{"date":"2019-12-31","value":-1837800000,"profit":false},{"date":"2020-12-31","value":-2268400000,"profit":false},{"date":"2021-12-31","value":-90400,"profit":false},{"date":"2022-12-31","value":-1970100000,"profit":false},{"date":"2023-12-31","value":-4540900000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (18.16M) | (22.71M) | (904.00) | (19.70M) | (42.12M) | [{"date":"2019-12-31","value":-1815500000,"profit":false},{"date":"2020-12-31","value":-2270700000,"profit":false},{"date":"2021-12-31","value":-90400,"profit":false},{"date":"2022-12-31","value":-1970100000,"profit":false},{"date":"2023-12-31","value":-4212400000,"profit":false}] |
Income Taxes | - | - | (47.21M) | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-4721000000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | - | - | (19.70M) | (42.12M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1970100000,"profit":false},{"date":"2023-12-31","value":-4212400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (18.16M) | (22.71M) | (904.00) | (19.70M) | (42.12M) | [{"date":"2019-12-31","value":-1815500000,"profit":false},{"date":"2020-12-31","value":-2270700000,"profit":false},{"date":"2021-12-31","value":-90400,"profit":false},{"date":"2022-12-31","value":-1970100000,"profit":false},{"date":"2023-12-31","value":-4212400000,"profit":false}] |
EPS (Diluted) | - | (0.16) | (23.80) | (18.70) | (6.32) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-16,"profit":false},{"date":"2021-12-31","value":-2380,"profit":false},{"date":"2022-12-31","value":-1870,"profit":false},{"date":"2023-12-31","value":-631.68,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TRML | |
---|---|
Cash Ratio | 38.70 |
Current Ratio | 40.33 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TRML | |
---|---|
ROA (LTM) | -23.82% |
ROE (LTM) | -31.82% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TRML | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.02 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.98 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TRML | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.59 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Tourmaline Bio Inc. (TRML) share price today is $20.601
Yes, Indians can buy shares of Tourmaline Bio Inc. (TRML) on Vested. To buy Tourmaline Bio Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TRML stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tourmaline Bio Inc. (TRML) via the Vested app. You can start investing in Tourmaline Bio Inc. (TRML) with a minimum investment of $1.
You can invest in shares of Tourmaline Bio Inc. (TRML) via Vested in three simple steps:
The 52-week high price of Tourmaline Bio Inc. (TRML) is $48.31. The 52-week low price of Tourmaline Bio Inc. (TRML) is $12.12.
The price-to-earnings (P/E) ratio of Tourmaline Bio Inc. (TRML) is
The price-to-book (P/B) ratio of Tourmaline Bio Inc. (TRML) is 1.59
The dividend yield of Tourmaline Bio Inc. (TRML) is 0.00%
The market capitalization of Tourmaline Bio Inc. (TRML) is $509.52M
The stock symbol (or ticker) of Tourmaline Bio Inc. is TRML